New hope for Tough-to-Treat ovarian cancer
NCT ID NCT05467670
Summary
This study is testing a new three-drug combination for women with recurrent ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if adding an experimental drug called ALX148 to two existing treatments (liposomal doxorubicin and pembrolizumab) is safe and can help shrink tumors. The study will enroll about 16 participants to measure how well the tumors respond and how long the treatment keeps the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.